December 9, 2024
TOPLINE: Increased cutaneous carbonyl stress is linked to slower nerve conduction in patients with metabolically well-controlled, recent-onset type 2 diabetes (T2D) and can predict the development […]
December 9, 2024
TOPLINE: Compared with a standard dosing regimen, a reduced-dose glucocorticoid regimen is associated with an increased risk for disease progression, relapse, death, or kidney failure in […]
December 9, 2024
TOPLINE: Among pregnant patients with chronic hypertension, delivery at 39 weeks of gestation provides an optimal balance between stillbirth risk and neonatal outcomes. Analysis of 227,977 […]
December 6, 2024
TOPLINE: International paediatric type 1 diabetes (T1D) registry data show improvement from 2013 to 2022 in average A1c and the proportion of children with T1D meeting […]
December 6, 2024
TOPLINE: People with type 2 diabetes (T2D) die from infections at a higher rate than similar people without diabetes, and the overall burden appears greater than […]
December 6, 2024
TOPLINE: Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4) inhibitors in […]
December 6, 2024
TOPLINE: Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when […]
December 6, 2024
TOPLINE: An analysis of acne-specific patient-reported outcome measures (PROMs) identified LGBTQ+-noninclusive language in four of nine measures, with heteronormative terms used in three of six measures […]
December 6, 2024
TOPLINE: For patients with early-stage ERBB2 (formerly HER2)–positive breast cancer, injections of increasing doses of autologous conventional type 1 dendritic cells (cDC1) combined with ERBB2-targeted antibodies […]